title: [A clinical trial of astromicin, a new aminoglycoside antibiotic, in thoracotomized patients and astromicin concentrations in the lung tissue].
abstract: There have been no report on concentrations in human lung tissue of aminoglycoside antibiotics which are frequently used in combination with cephem antibiotics in the treatment of severe respiratory infections. The authors examined lung tissue concentration of astromicin (ASTM) during clinical trials in thoracotomized patients using intravenous drip infusion just before operation. And the following conclusions have been obtained: 1. The average peak serum level obtained upon intravenous drip infusion of ASTM 200 mg for 1 hour just before operation was 11.2 micrograms/ml at 1 hour after starting the administration and half-life of ASTM in beta phase was 2.90 hours. 2. ASTM concentrations in the lung tissue upon 1 hour intravenous drip infusion just before operation at a dose level of 200 mg reached a maximum at 2 hours after the start of the administration averaging 7.7 micrograms/ml and were 27.7-68.8% of serum peak level. 3. Bronchiolar concentrations of ASTM 200 mg upon 1 hour intravenous drip infusion just before operation were 33.0-72.3% of peak serum level. These concentrations appear to be sufficient for the treatment of target infections. 4. The 1 hour intravenous drip infusion of ASTM 200 mg appeared to be clinically safety and useful as was the intramuscular injection of ASTM 200 mg.
authors.affiliation: Department of Thoracic Surgery, School of Medicine, Nagoya University.
authors.forename: M
authors.initials: M
authors.lastname: Imaizumi
authors.forename: T
authors.initials: T
authors.lastname: Niimi
authors.forename: Y
authors.initials: Y
authors.lastname: Uchida
authors.forename: M
authors.initials: M
authors.lastname: Asaoka
authors.forename: T
authors.initials: T
authors.lastname: Ozika
authors.forename: Y
authors.initials: Y
authors.lastname: Amano
authors.forename: T
authors.initials: T
authors.lastname: Uchida
authors.forename: K
authors.initials: K
authors.lastname: Hirai
authors.forename: M
authors.initials: M
authors.lastname: Kazita
authors.forename: T
authors.initials: T
authors.lastname: Abe
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D001980:Bronchi / Q000378:metabolism; D002511:Cephalosporins / Q000008:administration & dosage / Q000009:adverse effects; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005839:Gentamicins / Q000493:pharmacokinetics; D006207:Half-Life; D006801:Humans; D007262:Infusions, Intravenous; D008168:Lung / Q000378:metabolism*; D008175:Lung Neoplasms / Q000378:metabolism / Q000601:surgery; D008297:Male; D008875:Middle Aged; D011292:Premedication; D013908:Thoracotomy; D014018:Tissue Distribution
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D005839:Gentamicins; C023384:fortimicin A